Merge bids $22M for Confirma

Article

Other headlinesFuji lands multiple XR deal

Merge bids $22M for Confirma
Merge Healthcare is making a $22 million bid for privately held Confirma, a developer of computer-aided detection software for the analysis of breast and prostate MR studies. If the all-stock deal goes through, as expected in September, 5.6 million shares of Merge will trade hands at an estimated value of $3.897 per share, giving Confirma investors an 8.5% stake in Merge. Short-term synergies cited by Merge when the company announced the proposed deal include leveraging international and OEM distribution channels to increase the customer base beyond the 1200 Confirma software packages currently installed.  Merge would also seek to integrate Confirma and Merge breast imaging solutions. In the midterm, CAD-based technologies from Confirma may be used in clinical trials, a market segment that will open up with last month’s acquisition of etrials Worldwide. Over the long term, Merge wants to expand the use of CAD to improve efficiency in medical practice, namely in established markets where imaging costs are coming under fire.


Fuji lands multiple XR deal
FujiFilm Medical Systems USA has installed five FCR Go digital portable x-ray systems at Halifax Medical Center in Daytona Beach, FL.  The system uses computed radiography plates and an onboard reader to perform radiography throughout the hospital, which provides a 24-hour emergency department, the largest in the state of Florida, and East Central Florida’s first and only pediatric intensive care unit. Halifax is the area's only Level II Trauma Center.

 

 

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.